search 2013 adfgs

Diagnostics and Personalized Medicine Committee

The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey.
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.

Shiv Krishnan, Ph.D., Senior Director, Scouting & Partnering – US of Sanofi R&D; Elias Zerhouni, M.D., President, Global R&D of Sanofi; Kathleen Otto, Vice President, Business Development of BioNJ; G. Steven Burrill, CEO of Burrill & Company; Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform of Sanofi; and Edward Abrahams, Ph.D., President of the Personzalized Medicine Coalition at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

G. Steven Burrill, CEO of Burrill & Company; Debbie Hart, President and CEO of BioNJ; Shiv Krishnan, Ph.D., Senior Director, Scouting and Partnering – US of Sanofi R&D; and Roomi Nusrat, M.D., CEO of Aesclepius Sciences LLC at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

Past Events

June 6, 2013: Second Annual Diagnostics & Personalized Medicine Innovation Summit
December 13, 2012: Diagnostics & Personalized Medicine Breakfast Briefing
March 14, 2012: Diagnostics and Personalized Medicine Innovation Summit & Funding Roundtable
May 23-24, 2011: BioPartnering Conference: Bringing Together the Biotech, Diagnostics and Big Pharma Communities.
May 5, 2011: Diagnostics and Personalized Medicine Webinar
September 2010: New Jersey Gets Personalized Breakfast Briefing
July 2010: Kickoff Diagnostic Webinar Featuring G. Steven Burrill

Committee Members

Pascal Yvon, PharmD, MBA, Committee Co-Chair, President, BioSciences Expansion
Yamo Deniz, M.D., Committee Co-Chair, Chief Medical Officer, Global Head, Medical & PV, GE Healthcare Life Sciences
Steve Carchedi, Founding Co-Chair
David Avitabile, President, JFK Communications
G. Steven Burrill, Chief Executive Officer, Burrill & Company
Peter Hoehn, Vice President, Clinical Labs, Janssen Diagnostics
Christopher Moxham, Ph.D., Associate Vice President, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co.
Roomi Nusrat MD, Aesclepius Sciences
Kathleen Otto, Vice President, Business Development, BioNJ
Panna Sharma, Chief Executive Officer, Cancer Genetics, Inc.
Samir Tari M.D., Founder, PCAsso Diagnostics
Peter Tolias, Ph.D., Director, Center for Healthcare Innovation and Professor, Department of Chemistry, Chemical Biology and Biomedical Engineering, Stevens Institute of Technology

Members of the BioNJ Diagnostics and Personalized Medicine Committee join May 2011 Webinar Panelists at BioNJ Headquarters.


Video Archive

      

If you are interested in becoming a sponsor of the BioNJ Diagnostics and Personalized Medicine Committee, please contact Kathleen Otto at KOtto@BioNJ.org or by phone at 609-890-3185.